Acuta Capital Partners LLC Acquires New Position in Benitec Biopharma Inc. (NASDAQ:BNTC)

Acuta Capital Partners LLC bought a new position in Benitec Biopharma Inc. (NASDAQ:BNTC) during the third quarter, Holdings Channel reports. The institutional investor bought 29,800 shares of the biotechnology company’s stock, valued at approximately $274,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,102 shares during the period. Simplify Asset Management Inc. bought a new stake in shares of Benitec Biopharma in the 2nd quarter worth $358,000. Janus Henderson Group PLC grew its holdings in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in Benitec Biopharma during the second quarter valued at $5,881,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNTC has been the topic of several recent analyst reports. Oppenheimer began coverage on Benitec Biopharma in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price target on the stock. Guggenheim initiated coverage on Benitec Biopharma in a report on Thursday, September 12th. They set a “buy” rating and a $17.00 target price on the stock. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Finally, JMP Securities boosted their price objective on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Monday, October 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $22.60.

Benitec Biopharma Stock Performance

BNTC stock opened at $9.73 on Thursday. Benitec Biopharma Inc. has a twelve month low of $2.69 and a twelve month high of $12.89. The business has a 50 day moving average price of $10.14 and a two-hundred day moving average price of $9.12.

Benitec Biopharma Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.